Lupin To Present Cancer Drug Data at ASCO 2025

27 May 2025 CW Team

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.

LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.

The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.

Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”

Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.

Presentation Details:

4. Date: 2 June 2025

5. Time: 1:30–4:30 pm CDT

6. Location: Hall A, McCormick Place, Chicago

7. Abstract No.: 3107 | Poster Board No.: 422

8. Trial Registration: CTRI/2023/07/054753

9. DOI: 10.1200/JCO.2025.43.16_suppl.3107

Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Infrastructure Urban

11 Mar 2026

India Expands Semiconductor Training To 500 Institutions

Under the Chips to Startups programme of the India Semiconductor Mission, the Union minister responsible for Railways, Information and Broadcasting, and Electronics and IT reported notable progress in talent development. He indicated that over the past four years substantial steps have been taken towards a 10-year target of training 85,000 engineers in semiconductor design. World-class EDA tools have been deployed in 315 academic institutions across the country to provide students with practical exposure to chip design. These EDA tools are supported by leading global firms and are accessible t..

Delhi Institutions Support India Semiconductor Mission

The Government of India has prioritised talent development through training, upskilling and workforce development under the Chips to Startups initiative of the India Semiconductor Mission, with officials noting progress in four years towards a 10-year target of training 85,000 engineers in semiconductor design. Electronic design automation tools provided by Synopsys, Cadence, Siemens, Renesas, Ansys and AMD have been deployed in 315 academic institutions, enabling students to gain practical chip design experience. Chips have been fabricated and tested at the Semiconductor Laboratory, Mohali, a..

NHA Announces Winners Of NHCX Hackathon At IIT Hyderabad

The National Health Authority (NHA) has concluded the NHCX Hackathon under the Ayushman Bharat Digital Mission (ABDM) to stimulate innovation around the National Health Claims Exchange (NHCX). The winning teams presented their solutions at the NHCX Innovation Meet held at IIT Hyderabad during a two-day event in March 2026 that also served as the hackathon grand finale. The hackathon itself ran from 22 to 28 February 2026 and aimed to accelerate paperless, transparent claims processing across India. The event was organised with a range of ecosystem partners, including the Insurance Regulatory a..